Nasally administered appetite suppressant

• US 20070020194A1
• Filed: 06/08/2006
• Published: 01/25/2007
• Est. Priority Date: 06/08/2005
• Status: Abandoned Application

• Current Assignee: Domaine Associates LLC, Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Original Assignee: Board of Supervisors of Louisiana State University Agricultural & Mechanical College (Louisiana State University System)
• Inventors: Greenway, Frank, Young, Linda
• Application Number:
  US11/449,417
• Publication Number:
  US 20070020194A1
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/24 having an amino or nitro group
• CPC Class Codes: A61K 31/4166 having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• CPC Class Codes: A61K 31/4745 condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48

Abstract

Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense of smell or taste in subjects prior to meals leads to decreased food intake, which ultimately leads to weight loss. The ability to deliver drugs to the CSF via intranasal application also provide anorexiant central effect.

Claims

1. A method of treating obesity in a mammal in need of such treatment comprising applying a sodium channel blocker to the mammal intranasally in an amount sufficient to decrease sensation of smell.

2. The method of claim 1, wherein the sodium channel blocker is lidocaine.

3. The method of claim 1, wherein the sodium channel blocker is applied before meals.

4. The method of claim 1, wherein the sodium channel blocker is in the form of a gel, powder, spray, liquid, or drop.

5. The method of claim 1, further comprising the administration of a vasoconstrictor in combination with the sodium channel blocker.

6. The method of claim 5, wherein the vasoconstrictor is selected from the group consisting of:

epinephrine, norepinephrine, endothelin, thromboxane, naphazoline nitrate, tetrahydrozoline hydrochloride, oxymetazoline hydrochloride, phenylephrine hydrochloride and tramazoline hydrochloride.

7. The method of claim 1, wherein the concentration of the sodium channel blocker is from about 0.05 to about 200 mg/ml.

8. The method of claim 1, wherein the sodium channel blocker is selected from the group consisting of:

lidocaine, mepivacaine, bupivacaine quinidine, lorcainide, procainamide, encainide, propafenone, moricizine, mexiletine, disopyramide, aprindine, phenytoin, tocainide, flecainide, procaine, benzocaine dibucaine, tetracaine, butacaine, cyclomethycaine and tetracaine.

9. The method of claim 1, further comprising the co-administration of a topical anesthetic to the oral mucosa or tongue to reduce taste sensation.

10. A method of treating obesity in a mammal in need of such treatment comprising applying a sodium channel blocker, a humectant, a pH buffer and a thickening agent to the mammal intranasally.

11. The method of claim 10, wherein the humectant is selected from sorbitol, mineral oil, vegetable oil, glycerol, soothing agents, membrane conditioners, sweeteners and combinations thereof.

12. The method of claim 10, wherein the pH buffer is selected from acetate, citrate, prolamine, carbonate and phosphate buffers.

13. The method of claim 10, wherein the thickening agent is selected from xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose and carbomer.